This study reported superior response of CLEC9A-NY-ESO-1 to activate antigen-specific CD8+ T cells ex vivo in melanoma patients compared to NY-ESO-1 conjugated to DEC-205 antibody or NY-ESO-1 conjugated to control antibody, showcasing the potential of using CLEC9A-NY-ESO-1 antibody to enhance the immune response against NY-ESO-1 positive tumours including sarcomas [123]. Here, CD8A is linked to neoplasm.